GO-203-2c

DRUG3 trials

Sponsors

Genus Oncology, LLC, Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute

Conditions

Acute Myeloid Leukemia, in RelapseMultiple MyelomaMultiple Myeloma in RelapseRecurrent Adult Acute Myeloid LeukemiaRefractory Multiple MyelomaSolid Tumors

Phase 1

Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas

CompletedNCT01279603

Genus Oncology, LLCSolid Tumors

Start: 2011-01-31End: 2013-05-31Updated: 2014-09-19

A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia

CompletedNCT02204085

Beth Israel Deaconess Medical CenterAcute Myeloid Leukemia, in Relapse, Recurrent Adult Acute Myeloid Leukemia

Start: 2014-09-01End: 2025-12-01Updated: 2026-04-03

GO-203-2C + Bortezomib For Relapsed Or Refractory MM

WithdrawnNCT02658396

Dana-Farber Cancer InstituteMultiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma

End: 2022-01-31Updated: 2017-07-05

Related Papers

Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research.

2025-05-221 citations